NCT06320080View on ClinicalTrials.gov

Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma.

PHASE1RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 30, 2024

Primary Completion Date

February 28, 2025

Study Completion Date

October 31, 2025

Conditions
Advanced Hepatocellular Carcinoma
Interventions
DRUG

TQB2223 injection

TQB2223 is an anti- lymphocyte activation gene-3 (LAG-3) antibody.

DRUG

Penpulimab Injection

Penpulimab Injection is an anti programmed death-1 (PD-1) antibody.

Trial Locations (3)

150000

NOT_YET_RECRUITING

Affiliated Cancer Hospital of Harbin Medical University, Harbin

410031

RECRUITING

Hunan Provincial Tumor Hospital, Changsha

430079

NOT_YET_RECRUITING

Hubei Provincial Tumor Hospital, Wuhan

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY